Edition:
United States

Beigene Ltd (BGNE.OQ)

BGNE.OQ on NASDAQ Stock Exchange Global Select Market

136.29USD
22 Jan 2019
Change (% chg)

$-0.00 (-0.00%)
Prev Close
$136.29
Open
$142.53
Day's High
$149.62
Day's Low
$135.33
Volume
134,003
Avg. Vol
204,206
52-wk High
$220.09
52-wk Low
$105.19

Chart for

About

BeiGene, Ltd. is principally engaged in biopharmaceutical business. The Company is mainly engaged in the research and development, production and sales of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company's main products include Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317) and... (more)

Overall

Beta: --
Market Cap(Mil.): $4,400.80
Shares Outstanding(Mil.): 3.26
Dividend: --
Yield (%): --

Financials

  BGNE.OQ Industry Sector
P/E (TTM): -- 69.71 33.71
EPS (TTM): -4.93 -- --
ROI: -57.59 8.99 14.48
ROE: -77.45 10.14 15.99

Chinese biotech BeiGene raises $903 million in HK's first secondary listing under new rules: sources

HONG KONG (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

Aug 02 2018

UPDATE 1-Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

* Deal is second under new rules for early-stage biotechs (Adds deal details, context)

Aug 02 2018

Chinese biotech BeiGene raises $903 mln in HK's first secondary listing under new rules -sources

HONG KONG, Aug 2 (Reuters/IFR) - Chinese Nasdaq-listed biotech BeiGene Ltd has raised $903 million after pricing its secondary listing in Hong Kong - the first under new exchange rules - near the top of an indicative range, three people close to the deal said on Thursday.

Aug 02 2018

Earnings vs. Estimates